BioDelivery Sciences (Nasdaq: BDSI) said Monday it has received a $2.5 million milestone payment from its European drug provider partner Meda.
The Raleigh-based drug development firm will receive another $2.5 million from its partner Meda when its breakthrough pain reliever goes on sale in Europe.
Pricing and registration approval in Europe triggered the first milestone payment.
BDSI licened rights for Onsolis to Beda for sale in the European Union under the name Breakyl.
Commercial launch is anticipated before the end of the year, BDSI said.
